Temple University School of Pharmacy, Philadelphia, PA 19140, USA.
J Clin Pharm Ther. 2010 Feb;35(1):1-9. doi: 10.1111/j.1365-2710.2009.01044.x.
The diminution in cognitive function reported to occur in patients treated with adjuvant cancer chemotherapy (a phenomenon known as 'chemo-fog, 'chemo-brain' or similar designation) is supported with varying degrees of evidence by prospective and retrospective clinical studies. However, the cognitive deficits are often subtle and the methodologies used to measure them not consistent. Additionally, patients might be able to compensate for the deficits, thereby leading to underestimates of the problem by this type of assessment. For these reasons, direct neuroimaging techniques might provide additional insight. The relatively few such studies, and fewer electrophysiological studies, offer an alternative way to evaluate changes that might be related to cognitive deficits in patients treated with cancer chemotherapeutic regimens.
接受辅助癌症化疗的患者报告的认知功能减退（一种被称为“化疗雾”、“化疗脑”或类似命名的现象）得到了前瞻性和回顾性临床研究的不同程度的证据支持。然而，认知缺陷往往很细微，用于测量这些缺陷的方法也不一致。此外，患者可能能够弥补这些缺陷，从而导致这种评估对问题的低估。出于这些原因，直接神经影像学技术可能提供额外的见解。相对较少的此类研究，以及更少的电生理学研究，提供了另一种评估与接受癌症化疗方案治疗的患者认知缺陷相关的变化的方法。
